BACKGROUND: The aim of this study was to assess the role of neoadjuvant imatinib in redefining treatment for gastrointestinal stromal tumors (GISTs). METHODS: A total of 76 patients were reviewed. Among them, 29 patients who were administered neoadjuvant imatinib for borderline resectable and locally advanced GISTs followed by surgery were analyzed. Adjuvant imatinib was administered based on risk stratification. RESULTS: The median age of the neoadjuvant imatinib group was 51 years. The median duration of neoadjuvant imatinib administration was 8.5 months. The response rate with neoadjuvant imatinib was 79.3%. Five patients, initially considered to have locally unresectable lesions, ultimately underwent resection (three R0, two R2). Another three patients, who had M1 disease, underwent R2 resection (due to the presence of metastasis) with complete resection of the primary lesion. In 19 patients, who would have originally required extensive surgery, underwent conservative surgery (R0). In two patients, neoadjuvant imatinib did not influence the final procedure. The postoperative complication rate was 13.8%, and there were no postoperative deaths. There was one locoregional recurrence and two cases of distant metastasis. The 1-, 2-, and 3-year overall survivals were each 100%. CONCLUSIONS: Neoadjuvant imatinib for locally advanced GISTs is a safe concept for downsizing, improving resectability, and aiding organ-preserving surgery. It also improves the chance of long-term survival. Surgery, however, remains the cornerstone of curative treatment of GISTs even after neoadjuvant imatinib.
BACKGROUND: The aim of this study was to assess the role of neoadjuvant imatinib in redefining treatment for gastrointestinal stromal tumors (GISTs). METHODS: A total of 76 patients were reviewed. Among them, 29 patients who were administered neoadjuvant imatinib for borderline resectable and locally advanced GISTs followed by surgery were analyzed. Adjuvant imatinib was administered based on risk stratification. RESULTS: The median age of the neoadjuvant imatinib group was 51 years. The median duration of neoadjuvant imatinib administration was 8.5 months. The response rate with neoadjuvant imatinib was 79.3%. Five patients, initially considered to have locally unresectable lesions, ultimately underwent resection (three R0, two R2). Another three patients, who had M1 disease, underwent R2 resection (due to the presence of metastasis) with complete resection of the primary lesion. In 19 patients, who would have originally required extensive surgery, underwent conservative surgery (R0). In two patients, neoadjuvant imatinib did not influence the final procedure. The postoperative complication rate was 13.8%, and there were no postoperative deaths. There was one locoregional recurrence and two cases of distant metastasis. The 1-, 2-, and 3-year overall survivals were each 100%. CONCLUSIONS: Neoadjuvant imatinib for locally advanced GISTs is a safe concept for downsizing, improving resectability, and aiding organ-preserving surgery. It also improves the chance of long-term survival. Surgery, however, remains the cornerstone of curative treatment of GISTs even after neoadjuvant imatinib.
Authors: Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson Journal: Lancet Date: 2004 Sep 25-Oct 1 Impact factor: 79.321
Authors: Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu Journal: Cancer Date: 2008-02-01 Impact factor: 6.860
Authors: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss Journal: Hum Pathol Date: 2002-05 Impact factor: 3.466
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Aurore Blesius; Philippe A Cassier; François Bertucci; Jerome Fayette; Isabelle Ray-Coquard; Binh Bui; Antoine Adenis; Maria Rios; Didier Cupissol; David Pérol; Jean-Yves Blay; Axel Le Cesne Journal: BMC Cancer Date: 2011-02-15 Impact factor: 4.430
Authors: Ferdinando C M Cananzi; Bruno Lorenzi; Ajay Belgaumkar; Charlotte Benson; Ian Judson; Satvinder Mudan Journal: Langenbecks Arch Surg Date: 2014-01-12 Impact factor: 3.445
Authors: Shailesh V Shrikhande; Bhawna Sirohi; Savio G Barreto; Raju T Chacko; Purvish M Parikh; Jeremy Pautu; Supreeta Arya; Prachi Patil; Srinivas C Chilukuri; B Ganesh; Tanvir Kaur; Deepak Shukla; Goura Shankar Rath Journal: Indian J Med Paediatr Oncol Date: 2014-10
Authors: Nikolaos Vassos; Jens Jakob; Georg Kähler; Peter Reichardt; Alexander Marx; Antonia Dimitrakopoulou-Strauss; Nils Rathmann; Eva Wardelmann; Peter Hohenberger Journal: Cancers (Basel) Date: 2021-02-03 Impact factor: 6.639
Authors: Sara Renberg; Yifan Zhang; Fredrik Karlsson; Robert Bränström; Jan Åhlen; Li Jalmsell; Christina Linder-Stragliotto; Felix Haglund de Flon; Andri Papakonstantinou Journal: Int J Cancer Date: 2022-05-14 Impact factor: 7.316
Authors: M C Suresh Babu; Tamojit Chaudhuri; K Govind Babu; K C Lakshmaiah; D Lokanatha; Linu Abraham Jacob; A H Rudresha; K N Lokesh; L K Rajeev Journal: South Asian J Cancer Date: 2017 Jul-Sep